Covered recipient · General Payments record
JENNIFER MCVIGE
Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2022 · Entire year
$139,229.64
415 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2022 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $69,430.50 | 34 |
| Consulting Fee | $52,085.50 | 16 |
| Food and Beverage | $7,939.94 | 344 |
| Travel and Lodging | $7,121.43 | 14 |
| Honoraria | $2,550.00 | 2 |
| Grant | $87.90 | 2 |
| Education | $14.37 | 3 |
By paying entity
PY2022 · entire year · sorted by reported total
Page 3 of 9; records 101–150 of 415 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
JENNIFER MCVIGE
NPI 1649596495 · CMS profile ID 29232
Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology
AMHERST, NY
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 9; records 101–150 of 415 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1649596495?year=2022&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- JENNIFER MCVIGE, NPI 1649596495, CMS profile ID 29232. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 9; records 101–150 of 415 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1649596495?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- APA 7
- IndustryPayments. (2026). JENNIFER MCVIGE, NPI 1649596495, CMS profile ID 29232. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 9; records 101–150 of 415 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1649596495?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- Bluebook
- JENNIFER MCVIGE, NPI 1649596495, CMS profile ID 29232, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 9; records 101–150 of 415 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1649596495?year=2022&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2022
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30
415 matching records · $139,229.64 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–150 of 415.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Biohaven Pharmaceutical Holding Company Ltd. | $12.43 | 09/27/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 923669887 | CMS |
| Biohaven Pharmaceutical Holding Company Ltd. | $3.80 | 09/27/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 923669889 | CMS |
| Biohaven Pharmaceutical Holding Company Ltd. | $5.05 | 09/26/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 923669885 | CMS |
| Lilly USA, LLC | $2,800.00 | 09/26/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 918107809 | CMS |
| Lilly USA, LLC | $1,050.00 | 09/26/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 918107811 | CMS |
| Avanir Pharmaceuticals, Inc. | $7.53 | 09/22/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 935987477 | CMS |
| Avanir Pharmaceuticals, Inc. | $14.61 | 09/22/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 935987481 | CMS |
| ABBVIE INC. | $16.52 | 09/21/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 891145497 | CMS |
| Avanir Pharmaceuticals, Inc. | $1,140.00 | 09/21/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 935987077 | CMS |
| Lilly USA, LLC | $87.94 | 09/21/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 918127819 | CMS |
| Biohaven Pharmaceutical Holding Company Ltd. | $4.50 | 09/20/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 923669883 | CMS |
| Currax Pharmaceuticals LLC | $10.70 | 09/20/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 925768581 | CMS |
| Teva Pharmaceuticals USA, Inc. | $19.40 | 09/20/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 954434477 | CMS |
| ABBVIE INC. | $23.70 | 09/15/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 891145495 | CMS |
| UCB, Inc. | $18.77 | 09/15/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 965171143 | CMS |
| ABBVIE INC. | $31.51 | 09/13/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 891145493 | CMS |
| Biohaven Pharmaceutical Holding Company Ltd. | $3.94 | 09/13/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 923669881 | CMS |
| Neurelis, Inc. | $1,202.00 | 09/13/2022 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 950154633 | CMS |
| ABBVIE INC. | $22.39 | 09/09/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 891145491 | CMS |
| Lundbeck LLC | $18.17 | 09/09/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 945778663 | CMS |
| Amgen Inc. | $14.10 | 09/07/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 939342539 | CMS |
| Biohaven Pharmaceutical Holding Company Ltd. | $6.14 | 09/06/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 923669879 | CMS |
| Supernus Pharmaceuticals, Inc. | $21.37 | 08/31/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 953001007 | CMS |
| ABBVIE INC. | $2,370.00 | 08/30/2022 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 891145487 | CMS |
| ABBVIE INC. | $26.14 | 08/30/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 891145489 | CMS |
| Biohaven Pharmaceutical Holding Company Ltd. | $4.00 | 08/30/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 923669877 | CMS |
| Collegium Pharmaceutical, Inc. | $7.28 | 08/30/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 914536175 | CMS |
| Collegium Pharmaceutical, Inc. | $1.65 | 08/30/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 914536179 | CMS |
| IMPEL PHARMACEUTICALS INC. | $70.45 | 08/30/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 962316993 | CMS |
| Biohaven Pharmaceutical Holding Company Ltd. | $4.89 | 08/29/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 923669875 | CMS |
| ABBVIE INC. | $464.64 | 08/26/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 891145477 | CMS |
| ABBVIE INC. | $312.17 | 08/26/2022 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 891145479 | CMS |
| ABBVIE INC. | $82.88 | 08/26/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 891145481 | CMS |
| ABBVIE INC. | $5,530.00 | 08/26/2022 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 891145483 | CMS |
| ABBVIE INC. | $12.62 | 08/26/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 891145485 | CMS |
| ABBVIE INC. | $85.32 | 08/25/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 891145473 | CMS |
| ABBVIE INC. | $1,580.00 | 08/25/2022 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 891145475 | CMS |
| Teva Pharmaceuticals USA, Inc. | $18.02 | 08/25/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 954434459 | CMS |
| Avanir Pharmaceuticals, Inc. | $32.60 | 08/23/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 935979581 | CMS |
| Biohaven Pharmaceutical Holding Company Ltd. | $5.49 | 08/23/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 923669873 | CMS |
| Collegium Pharmaceutical, Inc. | $2.87 | 08/23/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 914533335 | CMS |
| Currax Pharmaceuticals LLC | $5.28 | 08/23/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 925768603 | CMS |
| Biohaven Pharmaceutical Holding Company Ltd. | $5.62 | 08/22/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 923669871 | CMS |
| Collegium Pharmaceutical, Inc. | $5.89 | 08/22/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 914532893 | CMS |
| Teva Pharmaceuticals USA, Inc. | $22.29 | 08/19/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 954434365 | CMS |
| UCB, Inc. | $22.71 | 08/19/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 907985781 | CMS |
| Amgen Inc. | $15.94 | 08/17/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 939342537 | CMS |
| Biohaven Pharmaceutical Holding Company Ltd. | $7.04 | 08/17/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 923669869 | CMS |
| Amneal Pharmaceuticals LLC | $12.09 | 08/16/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 956587949 | CMS |
| Biohaven Pharmaceutical Holding Company Ltd. | $11.59 | 08/16/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 923669867 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $225,328.64 | 62 |
| PY2024 | Recipient | $6.54 | 2 |
| PY2024 | Principal investigator | $322,216.84 | 74 |
| PY2023 | Recipient | $17,037.88 | 10 |
| PY2023 | Principal investigator | $133,263.56 | 27 |
| PY2022 | Recipient | $1,195.37 | 4 |
| PY2022 | Principal investigator | $291,698.59 | 64 |
| PY2021 | Recipient | $534.76 | 2 |
| PY2021 | Principal investigator | $262,972.41 | 67 |
| PY2020 | Recipient | $5,239.88 | 3 |
| PY2020 | Principal investigator | $279,757.06 | 29 |
| PY2019 | Recipient | $1,142.95 | 1 |
| PY2019 | Principal investigator | $431,636.45 | 21 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
62 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | ABBVIE INC. | $600.00 | 12/31/2025 | Non-covered Recipient Entity DENT NEUROLOGIC INSTITUTE | A Phase 3, Multicenter, 12-Week, Double Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atogepant for the Preventive Treatment of Episodic Migraine in Pediatric Subjects 6-17 years of age. | No dispute reported | 06/30/2026 | 1202532993 |
| Principal investigator 1 | ABBVIE INC. | $508.76 | 12/31/2025 | Non-covered Recipient Entity DENT NEUROLOGIC INSTITUTE | A Phase 3, Multicenter, 12-Week, Double Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atogepant for the Preventive Treatment of Chronic Migraine in Pediatric Subjects 12 to 17 Years of Age | No dispute reported | 06/30/2026 | 1202532995 |
| Principal investigator 1 | ABBVIE INC. | $600.00 | 12/31/2025 | Non-covered Recipient Entity DENT NEUROLOGIC INSTITUTE | A Multicenter, Open-label, Extension Study to Evaluate the Long-term Safety and Tolerability of Atogepant in Pediatric Subjects 6 to 17 years of age with Migraine | No dispute reported | 06/30/2026 | 1202532997 |
| Principal investigator 1 | ABBVIE INC. | $1,440.00 | 12/31/2025 | Non-covered Recipient Entity DENT NEUROLOGIC INSTITUTE | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Single-attack Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Oral Ubrogepant in the Acute Treatment of Migraine With or Without Aura in Children and Adolescents (Ages 6-17) | No dispute reported | 06/30/2026 | 1202532999 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $1,500.00 | 12/19/2025 | Non-covered Recipient Entity DENT NEUROSCIENCES RESEARCH CENTER | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1244048543 |
| Principal investigator 1 | ABBVIE INC. | $5,480.00 | 12/11/2025 | Non-covered Recipient Entity DENT NEUROSCIENCES RESEARCH | A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine | No dispute reported | 06/30/2026 | 1202530098 |
| Principal investigator 1 | ABBVIE INC. | $395.55 | 12/04/2025 | Non-covered Recipient Entity DENT NEUROSCIENCES RESEARCH | Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) | No dispute reported | 06/30/2026 | 1202527798 |
| Principal investigator 1 | ABBVIE INC. | $5,600.00 | 12/04/2025 | Non-covered Recipient Entity DENT NEUROSCIENCES RESEARCH | Observational Study of Oral Atogepant to Evaluate Real-World Effectiveness in Adult Participants With Migraine (CORNERSTONE) | No dispute reported | 06/30/2026 | 1202527800 |
| Principal investigator 1 | ABBVIE INC. | $25.00 | 12/04/2025 | Non-covered Recipient Entity DENT NEUROSCIENCES RESEARCH | Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine | No dispute reported | 06/30/2026 | 1202528000 |
| Principal investigator 1 | Ipsen Innovation | $600.00 | 12/04/2025 | Non-covered Recipient Entity Dent Neurosciences Research Center | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184302717 |
| Principal investigator 1 | Ipsen Innovation | $800.00 | 12/04/2025 | Non-covered Recipient Entity Dent Neurosciences Research Center | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184302719 |
| Principal investigator 1 | Ipsen Innovation | $1,250.00 | 12/04/2025 | Non-covered Recipient Entity Dent Neurosciences Research Center | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184302721 |
| Principal investigator 1 | Ipsen Innovation | $500.00 | 12/04/2025 | Non-covered Recipient Entity Dent Neurosciences Research Center | Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants | No dispute reported | 06/30/2026 | 1184302723 |
| Principal investigator 1 | PFIZER INC. | $908.10 | 11/24/2025 | Non-covered Recipient Entity Dent Neurosciences Research Center INC | PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228817877 |
| Principal investigator 1 | ABBVIE INC. | $25,200.00 | 11/05/2025 | Non-covered Recipient Entity DENT NEUROSCIENCES RESEARCH | Observational Study of Oral Atogepant to Evaluate Real-World Effectiveness in Adult Participants With Migraine (CORNERSTONE) | No dispute reported | 06/30/2026 | 1202522731 |
| Principal investigator 1 | ABBVIE INC. | $2,216.70 | 11/04/2025 | Non-covered Recipient Entity DENT NEUROSCIENCES RESEARCH | Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) | No dispute reported | 06/30/2026 | 1202520961 |
| Principal investigator 1 | ABBVIE INC. | $2,124.00 | 11/04/2025 | Non-covered Recipient Entity DENT NEUROSCIENCES RESEARCH | Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine | No dispute reported | 06/30/2026 | 1202520963 |
| Principal investigator 1 | ABBVIE INC. | $4,083.00 | 10/09/2025 | Non-covered Recipient Entity DENT NEUROSCIENCES RESEARCH | Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine | No dispute reported | 06/30/2026 | 1202513845 |
| Principal investigator 1 | ABBVIE INC. | $2,380.00 | 10/09/2025 | Non-covered Recipient Entity DENT NEUROSCIENCES RESEARCH | A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years | No dispute reported | 06/30/2026 | 1202513847 |
| Principal investigator 1 | ABBVIE INC. | $4,607.55 | 10/09/2025 | Non-covered Recipient Entity DENT NEUROSCIENCES RESEARCH | Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) | No dispute reported | 06/30/2026 | 1202513849 |
| Principal investigator 1 | ABBVIE INC. | $2,530.00 | 09/04/2025 | Non-covered Recipient Entity DENT NEUROSCIENCES RESEARCH | A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years | No dispute reported | 06/30/2026 | 1202509960 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $1,500.00 | 09/04/2025 | Non-covered Recipient Entity DENT NEUROSCIENCES RESEARCH CENTER | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Episodic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1244048545 |
| Principal investigator 1 | ABBVIE INC. | $1,306.00 | 09/03/2025 | Non-covered Recipient Entity DENT NEUROSCIENCES RESEARCH | Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine | No dispute reported | 06/30/2026 | 1202508320 |
| Principal investigator 1 | ABBVIE INC. | $1,582.20 | 09/03/2025 | Non-covered Recipient Entity DENT NEUROSCIENCES RESEARCH | Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) | No dispute reported | 06/30/2026 | 1202508322 |
| Principal investigator 1 | PFIZER INC. | $1,986.03 | 08/27/2025 | Non-covered Recipient Entity Dent Neurosciences Research Center INC | PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228834180 |
| Principal investigator 1 | ABBVIE INC. | $4,760.00 | 08/06/2025 | Non-covered Recipient Entity DENT NEUROSCIENCES RESEARCH | A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years | No dispute reported | 06/30/2026 | 1202503233 |
| Principal investigator 1 | ABBVIE INC. | $2,895.75 | 08/05/2025 | Non-covered Recipient Entity DENT NEUROSCIENCES RESEARCH | Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) | No dispute reported | 06/30/2026 | 1202501916 |
| Principal investigator 1 | PFIZER INC. | $1,815.66 | 07/29/2025 | Non-covered Recipient Entity Dent Neurosciences Research Center INC | PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228840940 |
| Principal investigator 1 | ABBVIE INC. | $8,960.00 | 07/08/2025 | Non-covered Recipient Entity DENT NEUROSCIENCES RESEARCH | Observational Study of Oral Atogepant to Evaluate Real-World Effectiveness in Adult Participants With Migraine (CORNERSTONE) | No dispute reported | 06/30/2026 | 1202497308 |
| Principal investigator 1 | ABBVIE INC. | $3,971.70 | 07/02/2025 | Non-covered Recipient Entity DENT NEUROSCIENCES RESEARCH | Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) | No dispute reported | 06/30/2026 | 1202495709 |
| Principal investigator 1 | ABBVIE INC. | $4,233.00 | 07/02/2025 | Non-covered Recipient Entity DENT NEUROSCIENCES RESEARCH | Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine | No dispute reported | 06/30/2026 | 1202495711 |
| Principal investigator 1 | ABBVIE INC. | $249.75 | 07/02/2025 | Non-covered Recipient Entity DENT NEUROSCIENCES RESEARCH | Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) | No dispute reported | 06/30/2026 | 1202495713 |
| Principal investigator 1 | ABBVIE INC. | $1,120.00 | 07/02/2025 | Non-covered Recipient Entity DENT NEUROSCIENCES RESEARCH | Observational Study of Oral Atogepant to Evaluate Real-World Effectiveness in Adult Participants With Migraine (CORNERSTONE) | No dispute reported | 06/30/2026 | 1202495715 |
| Principal investigator 1 | Eli Lilly and Company | $56.25 | 06/24/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES OF TUCSON | A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF GALCANEZUMAB IN ADOLESCENT PATIENTS 12 TO 17 YEARS OF AGE WITH CHRONIC MIGRAINE THE REBUILD 2 STUDY | No dispute reported | 06/30/2026 | 1187884424 |
| Principal investigator 1 | PFIZER INC. | $2,560.68 | 06/13/2025 | Non-covered Recipient Entity Dent Neurosciences Research Center INC | PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228844876 |
| Principal investigator 1 | ABBVIE INC. | $1,811.70 | 06/03/2025 | Non-covered Recipient Entity DENT NEUROSCIENCES RESEARCH | Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) | No dispute reported | 06/30/2026 | 1202488011 |
| Principal investigator 1 | ABBVIE INC. | $4,037.85 | 06/03/2025 | Non-covered Recipient Entity DENT NEUROSCIENCES RESEARCH | Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) | No dispute reported | 06/30/2026 | 1202488013 |
| Principal investigator 1 | ABBVIE INC. | $653.00 | 06/03/2025 | Non-covered Recipient Entity DENT NEUROSCIENCES RESEARCH | Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine | No dispute reported | 06/30/2026 | 1202488015 |
| Principal investigator 1 | ABBVIE INC. | $2,039.00 | 06/03/2025 | Non-covered Recipient Entity DENT NEUROSCIENCES RESEARCH | A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine | No dispute reported | 06/30/2026 | 1202488017 |
| Principal investigator 1 | ABBVIE INC. | $10,052.00 | 06/03/2025 | Non-covered Recipient Entity DENT NEUROSCIENCES RESEARCH | A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years | No dispute reported | 06/30/2026 | 1202488099 |
| Principal investigator 1 | ABBVIE INC. | $2,800.00 | 05/07/2025 | Non-covered Recipient Entity DENT NEUROSCIENCES RESEARCH | Observational Study of Oral Atogepant to Evaluate Real-World Effectiveness in Adult Participants With Migraine (CORNERSTONE) | No dispute reported | 06/30/2026 | 1202483551 |
| Principal investigator 1 | ABBVIE INC. | $2,216.70 | 05/06/2025 | Non-covered Recipient Entity DENT NEUROSCIENCES RESEARCH | Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) | No dispute reported | 06/30/2026 | 1202481935 |
| Principal investigator 1 | ABBVIE INC. | $2,308.50 | 05/06/2025 | Non-covered Recipient Entity DENT NEUROSCIENCES RESEARCH | Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) | No dispute reported | 06/30/2026 | 1202481977 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $9,104.26 | 04/28/2025 | Non-covered Recipient Entity DENT NEUROSCIENCES RESEARCH CENTER | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine in Pediatric Patients 6 to 17 Years of Age | No dispute reported | 06/30/2026 | 1244048541 |
| Principal investigator 1 | PFIZER INC. | $6,567.89 | 04/24/2025 | Non-covered Recipient Entity Dent Neurosciences Research Center INC | PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228853471 |
| Principal investigator 1 | ABBVIE INC. | $2,540.00 | 04/03/2025 | Non-covered Recipient Entity DENT NEUROSCIENCES RESEARCH | Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine | No dispute reported | 06/30/2026 | 1202473421 |
| Principal investigator 1 | ABBVIE INC. | $22,960.00 | 04/03/2025 | Non-covered Recipient Entity DENT NEUROSCIENCES RESEARCH | Observational Study of Oral Atogepant to Evaluate Real-World Effectiveness in Adult Participants With Migraine (CORNERSTONE) | No dispute reported | 06/30/2026 | 1202473425 |
| Principal investigator 1 | ABBVIE INC. | $2,039.00 | 04/03/2025 | Non-covered Recipient Entity DENT NEUROSCIENCES RESEARCH | A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine | No dispute reported | 06/30/2026 | 1202473429 |
| Principal investigator 1 | ABBVIE INC. | $4,700.70 | 04/03/2025 | Non-covered Recipient Entity DENT NEUROSCIENCES RESEARCH | Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) | No dispute reported | 06/30/2026 | 1202473433 |
| Principal investigator 1 | ABBVIE INC. | $1,400.00 | 03/07/2025 | Non-covered Recipient Entity DENT NEUROSCIENCES RESEARCH | P24-880 - Observational Study of Oral Atogepant to Evaluate Real-World Effectiveness in Adult Participants With Migraine (CORNERSTONE) | No dispute reported | 06/30/2026 | 1202460268 |
| Principal investigator 1 | ABBVIE INC. | $11,346.75 | 03/06/2025 | Non-covered Recipient Entity DENT NEUROSCIENCES RESEARCH | Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) | No dispute reported | 06/30/2026 | 1202457197 |
| Principal investigator 1 | ABBVIE INC. | $2,096.55 | 03/06/2025 | Non-covered Recipient Entity DENT NEUROSCIENCES RESEARCH | Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) | No dispute reported | 06/30/2026 | 1202457201 |
| Principal investigator 1 | ABBVIE INC. | $1,959.00 | 03/06/2025 | Non-covered Recipient Entity DENT NEUROSCIENCES RESEARCH | M21-199 - Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine | No dispute reported | 06/30/2026 | 1202457205 |
| Principal investigator 1 | ABBVIE INC. | $6,978.15 | 02/05/2025 | Non-covered Recipient Entity DENT NEUROSCIENCES RESEARCH | Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) | No dispute reported | 06/30/2026 | 1202444167 |
| Principal investigator 1 | ABBVIE INC. | $8,275.50 | 02/05/2025 | Non-covered Recipient Entity DENT NEUROSCIENCES RESEARCH | Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) | No dispute reported | 06/30/2026 | 1202444171 |
| Principal investigator 1 | ABBVIE INC. | $1,858.00 | 02/05/2025 | Non-covered Recipient Entity DENT NEUROSCIENCES RESEARCH | M21-199 - Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine | No dispute reported | 06/30/2026 | 1202444497 |
| Principal investigator 1 | Eli Lilly and Company | $600.00 | 01/31/2025 | Non-covered Recipient Entity NEUROLOGY ASSOCIATES OF TUCSON | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF GALCANEZUMAB IN PATIENTS 6 TO 17 YEARS OF AGE WITH EPISODIC MIGRAINE - THE REBUILD STUDY | No dispute reported | 06/30/2026 | 1187886208 |
| Principal investigator 1 | PFIZER INC. | $832.50 | 01/23/2025 | Non-covered Recipient Entity Dent Neurosciences Research Center INC | PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228859099 |
| Principal investigator 1 | PFIZER INC. | $764.46 | 01/16/2025 | Non-covered Recipient Entity Dent Neurosciences Research Center INC | PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228859056 |
| Principal investigator 1 | Eli Lilly and Company | $9,966.00 | 01/07/2025 | Non-covered Recipient Entity DENT NEUROSCIENCES RESEARCH CENTER INC | A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF GALCANEZUMAB IN ADOLESCENT PATIENTS 12 TO 17 YEARS OF AGE WITH CHRONIC MIGRAINE THE REBUILD 2 STUDY | No dispute reported | 06/30/2026 | 1187878723 |
| Principal investigator 1 | ABBVIE INC. | $1,205.00 | 01/02/2025 | Non-covered Recipient Entity DENT NEUROSCIENCES RESEARCH | M21-199 - Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine | No dispute reported | 06/30/2026 | 1202433742 |
| Principal investigator 1 | ABBVIE INC. | $3,870.45 | 01/02/2025 | Non-covered Recipient Entity DENT NEUROSCIENCES RESEARCH | Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) | No dispute reported | 06/30/2026 | 1202433809 |
Ownership and Investment Interests
One row per program year and measure, newest year first · the amount invested and the value of the interest are never added together
| Program year | Measure | Amount | Records |
|---|---|---|---|
| PY2025 | Amount invested | $68,970.59 | 1 |
| PY2025 | Value of interest | $168,601.86 | 1 |
| PY2024 | Amount invested | $40,296.41 | 1 |
| PY2024 | Value of interest | $99,631.27 | 1 |
| PY2023 | Amount invested | $17,103.46 | 1 |
| PY2023 | Value of interest | $59,334.86 | 1 |
| PY2022 | Amount invested | $17,804.01 | 1 |
| PY2022 | Value of interest | $42,231.41 | 1 |
| PY2021 | Amount invested | $7,696.81 | 1 |
| PY2021 | Value of interest | $24,427.40 | 1 |
| PY2020 | Amount invested | $8,096.07 | 1 |
| PY2020 | Value of interest | $16,730.59 | 1 |
| PY2019 | Amount invested | $8,290.25 | 1 |
| PY2019 | Value of interest | $8,634.52 | 1 |
Ownership and Investment Interests are a separate CMS dataset, shown here separately and never added to payments.
Ownership and investment interests are reported as the value of an interest held, not as a payment received. They are a different measure from the payment total on this page and are never combined with it.
Ownership and Investment Interests records
Ordering applied by this site (program year, newest first, then company) · record values are shown as CMS published them
7 records · PY2019–2025
| Program year | Company | Amount invested | Value of interest | Terms of interest | Interest held by | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| PY2025 | NEUROLOGY PRACTICE CONSORTIUM GPO, LLC | $68,970.59 | $168,601.86 | Value of interest is a cumulative total calculated by adding year-over-year ownership values per provider. Payments are made to a group practice, not directly to the physician. We calculate ownership percentage/dollar amount invested by determining the percentage of overhead buy down per physician clinic as a result of the practice ownership in the GPO. | Physician Covered Recipient | No dispute reported | 06/30/2026 | 1246692284 |
| PY2024 | NEUROLOGY PRACTICE CONSORTIUM GPO, LLC | $40,296.41 | $99,631.27 | 1.) Value of interest is a cumulative total calculated by adding year-over-year ownership values per provider. 2.) Payments are made to a group practice rather than to a specific physician. The group practice owns 50% of the GPO. We calculate ownership percentage/dollar amount invested by determining the percentage of overhead buydown per physician clinic as a result of the practice ownership in the GPO. | Physician Covered Recipient | No dispute reported | 06/30/2026 | 1146408855 |
| PY2023 | NEUROLOGY PRACTICE CONSORTIUM GPO, LLC | $17,103.46 | $59,334.86 | 1.) Value of interest is a cumulative total calculated by adding year-over-year ownership values per provider. 2.) Payments are made to a group practice rather than to a specific physician. The group practice owns 50% of the GPO. We calculate ownership percentage/dollar amount invested by determining the percentage of overhead buydown per physician clinic as a result of the practice ownership in the GPO. | Physician Covered Recipient | No dispute reported | 06/30/2026 | 1056981129 |
| PY2022 | NEUROLOGY PRACTICE CONSORTIUM GPO, LLC | $17,804.01 | $42,231.41 | The organization the physician practices at owns 50% of the GPO, therefore 50% of the profit goes to the medical practice. | Physician Covered Recipient | No dispute reported | 06/30/2026 | 962020747 |
| PY2021 | NEUROLOGY PRACTICE CONSORTIUM GPO, LLC | $7,696.81 | $24,427.40 | The organization the physician practices at owns 50% of the GPO, therefore 50% of the profit goes to the medical practice. | Physician Covered Recipient | No dispute reported | 06/30/2026 | 851041375 |
| PY2020 | NEUROLOGY PRACTICE CONSORTIUM GPO, LLC | $8,096.07 | $16,730.59 | Physician is employed at outpatient neurology practice that owns a percentage of the GPO | Physician Covered Recipient | No dispute reported | 06/30/2026 | 753247345 |
| PY2019 | NEUROLOGY PRACTICE CONSORTIUM GPO, LLC | $8,290.25 | $8,634.52 | Physician is employed at outpatient neurology practice that owns a percentage of the GPO | Physician Covered Recipient | No dispute reported | 06/30/2026 | 708351947 |